SKYBIOTECH
SKYBIOTECH HEALTHCARE financials
- Market cap
- ₹27 Cr
Quarterly results
Q1 FY27: revenue down 79.5%, net profit down 2750.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 1 | 2 | 2 +20% | 1 −62% | 2 +79% | 0 −79% |
| EBITDA | 0 | -0 | -1 | 0 | -0 −1250% | -0 −45% | -1 +19% | -1 −762% |
| Net profit | -0 | -0 | -1 | -0 | -0 −24% | -0 −23% | -0 +72% | -1 −2750% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −30.8% 1Y
1Y: ₹174.45 on 9 Sept 2025 → ₹120.8. High ₹220 (30 Sept 2025), low ₹116.45 (24 Feb 2026).
Financials, as filed
Revenue grew 38.1% a year over 1 year, FY25 to FY26. Operating margin widened to -20.8%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹5 Cr | ₹7 Cr |
| Operating profit | ₹-1 Cr | ₹-1 Cr |
| Operating margin | -27.6% | -20.8% |
| Interest | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr |
| Net profit | ₹-1 Cr | ₹-1 Cr |
| Net margin | -28.6% | -15.6% |
| Cash from operations | ₹-1 Cr | ₹-2 Cr |
| Free cash flow | ₹-1 Cr | ₹-2 Cr |
| ROCE | — | -9.3% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Equity capital | — | ₹2 Cr | ₹2 Cr |
| Reserves | — | ₹7 Cr | ₹6 Cr |
| Borrowings | — | ₹7 Cr | ₹8 Cr |
| Other liabilities | — | ₹4 Cr | ₹3 Cr |
| Total liabilities | — | ₹20 Cr | ₹19 Cr |
| Fixed assets | — | ₹12 Cr | ₹12 Cr |
| Capital work in progress | — | ₹0 Cr | ₹0 Cr |
| Investments | — | ₹2 Cr | ₹2 Cr |
| Other assets | — | ₹6 Cr | ₹6 Cr |
| Total assets | — | ₹20 Cr | ₹19 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 5% to 632.
- Promoters
- 63.5%
- Public
- 36.5%
Since Jun 2025
- Public +0.01 pp
- Promoters 0.00 pp
How it drifted, 12 quarters
Over this window promoters went from 57.8% to 63.5% — +5.7 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 57.8%, Public 42.2%.Dec '23: Promoters 62.7%, Public 37.3%.Mar '24: Promoters 62.7%, Public 37.3%.Jun '24: Promoters 62.7%, Public 37.3%.Sep '24: Promoters 62.7%, Public 37.3%.Dec '24: Promoters 62.7%, Public 37.3%.Mar '25: Promoters 63.5%, Public 36.5%.Jun '25: Promoters 63.5%, Public 36.5%.Sep '25: Promoters 63.5%, Public 36.5%.Dec '25: Promoters 63.5%, Public 36.5%.Mar '26: Promoters 63.5%, Public 36.5%.Jun '26: Promoters 63.5%, Public 36.5%.
Who is on the register
Named in the Jun 2026 filing
Every holder of SKYBIOTECH HEALTHCARE LIMITED above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Prakash Chandra Rathi Huf . | 45.16% | unchanged |
| Poonam Prakash Rathi . | 13.01% | unchanged |
| Rajlaxmi Ganesh Totala . | 5.22% | unchanged |
| Ganesh Shivprasad Lahoti | 4.44% | unchanged |
| Sangita Ashish Rathi | 3.26% | unchanged |
| Kaustubh Ashish Rathi | 3.26% | unchanged |
| Smita Shivprasad Lahoti | 2.09% | unchanged |
| Alka Pravin Joshi . | 1.96% | unchanged |
| Rakesh Satya Narayan Rathi | 1.39% | unchanged |
| Pankti Chetan Bhansali | 1.31% | unchanged |
| Pavan Madanlal Malpani | 1.31% | unchanged |
| Harshala Rajesh Kothari | 1.11% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse SKYBIOTECH HEALTHCARE LIMITED
Guides on how to read this kind of business and the numbers that matter.